- Approval Id
- 14740e5fbf608a6f
- Drug Approval Emc Name
- HBVAXPRO 40 micrograms, suspension for injection
- Drug Name
- HBVAXPRO 40 micrograms, suspension for injection
- Company Address
- 120 Moorgate, London, EC2M 6UR, UK
- Company Website
- http://www.msd-uk.com/
- Company Telephone
- +44 (0)208 154 8000 (all hours)
- Company Medical Info Email
- medicalinformationuk@msd.com
- Company Customer Care Direct Line
- +44 (0)208 154 8001
- Atc Code
- J07BC01
- Legal Category
- Prescription only medicine
- Authorisation Holder
- Merck Sharp & Dohme (UK) Limited
120 Moorgate
London
EC2M 6UR
United Kingdom
- Authorisation Number
- PLGB 53095/0026
- Authorisation Date
- 01/01/2021
- Instruction Authorisation Holder
- Merck Sharp & Dohme (UK) Limited
120 Moorgate
London
EC2M 6UR
United Kingdom
- Instruction Authorisation Number
- PLGB 53095/0026
- Instruction Authorisation Date
- 01/01/2021
- Instruction Composition
- One dose (1 mL) contains:
Hepatitis B virus surface antigen, recombinant (HBsAg) \\* 40 micrograms
Adsorbed on amorphous aluminium hydroxyphosphate sulfate (0.50 milligram Al+)
\\* produced in \*Saccharomyces cerevisiae\* (strain 2150-2-3) yeast by recombinant DNA technology.
This vaccine may contain traces of formaldehyde and potassium thiocyanate which are used during the manufacturing process. See sections 4.3, 4.4 and 4.8.
Excipient(s) with known effect:
Sodium less than 1mmol (23 mg) per dose.
For the full list of excipients, see section 6.1.
- Instruction Dosage Form
- Suspension for injection
Slightly opaque white suspension.
- Instruction Clinical Particulars
- 4.1 Therapeutic indications
HBVAXPRO is indicated for the active immunisation against hepatitis B virus infection caused by all known subtypes in predialysis and dialysis adult patients.
It can be expected that hepatitis D will also be prevented by immunisation with HBVAXPRO as hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection.4.2 Posology and method of administration
\*\*Posology\*\*
Predialysis and dialysis adult patients: 1 dose (1 mL) at each injection.
\*\*\*Primary vaccination\*\*:\*
A course of vaccination should include three injections:
Schedule 0, 1, 6 months: two injections with an interval of one month; a third injection 6 months after the first administration.
\*\*\*Booster:\*\*\*
A booster dose must be considered in these vaccinees if the antibody level against hepatitis B virus surface antigen (anti-HBsAg) after primary series is less than 10 IU/l.
In accordance with standard medical practice for hepatitis B vaccine administration, regular antibody testing should be done in haemodialysis patients. A booster dose should be given when antibody levels decline below 10 IU/l.
\*\*Special dosage recommendations for known or presumed exposure to hepatitis B virus (e.g. needlestick with contaminated needle):\*\*
- Hepatitis B immunoglobulin should be given as soon as possible after exposure (within 24 hours).
- The first dose of the vaccine should be given within 7 days of exposure and can be administered simultaneously with hepatitis B immunoglobulin but at a separate injection site.
- Serologic testing is also recommended, with the administration of subsequent doses of vaccine, if necessary, (i.e. according to the serologic status of the patient) for short and long term protection.
- In the case of unvaccinated or incompletely vaccinated individuals, additional doses should be given as in the recommended immunisation schedule.
\*\*Method of administration\*\*
This vaccine should be administered intramuscularly.
The deltoid muscle is the preferred site for injection in adults.
Do not inject intravascularly.
Exceptionally, the vaccine may be administered subcutaneously in patients with thrombocytopaenia or bleeding disorders.
Precautions to be taken before handling or administering the product: see section 6.6.4.3 Contraindications
- History of hypersensitivity to the active substance, or to any of the excipients, or trace residuals (e.g. formaldehyde and potassium thiocyanate), see sections 6.1 and 6.2.
- Vaccination should be postponed in individuals with a severe febrile illness or acute infection.4.4 Special warnings and precautions for use
\*\*Traceability\*\*
In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.
As with all injectable vaccines, appropriate medical treatment should always be readily available in case of rare anaphylactic reactions following the administration of the vaccine (see section 4.8).
This vaccine may contain traces of formaldehyde and potassium thiocyanate which are used during the manufacturing process. Therefore, hypersensitivity reactions may occur (see sections 2 and 4.8).
Use caution when vaccinating latex-sensitive individuals since the vial stopper contains dry natural latex rubber that may cause allergic reactions.
A number of factors have been observed to reduce the immune response to hepatitis B vaccines. These factors include older age, male gender, obesity, smoking, route of administration and some chronic underlying diseases. Consideration should be given to serological testing of those subjects who may be at risk of not achieving seroprotection following a complete course of HBVAXPRO. Additional doses may need to be considered for persons who do not respond or have a sub-optimal response to a course of vaccinations.
Because of the long incubation period of hepatitis B, it is possible for unrecognised hepatitis B infection to be present at the time of vaccination. The vaccine may not prevent hepatitis B infection in such cases.
The vaccine will not prevent infection caused by other agents such as hepatitis A, hepatitis C and hepatitis E and other pathogens known to infect the liver.
Caution should be exercised when prescribing to pregnant or breast-feeding women (see section 4.6).
Excipient(s) with known effect:
This medicinal product contains less than 1mmol sodium (23 mg) per dose, and is considered to be essentially sodium free.4.5 Interaction with other medicinal products and other forms of interaction
This vaccine can be administered:
- with hepatitis B immunoglobulin, at a separate injection site.
- to complete a primary immunisation course or as a booster dose in subjects who have previously received another hepatitis B vaccine.
- concomitantly with other vaccines, using separate sites and syringes.4.6 Fertility, pregnancy and lactation
\*\*Fertility:\*\*
HBVAXPRO has not been evaluated in fertility studies.
\*\*Pregnancy:\*\*
There is no clinical data on the use of HBVAXPRO in pregnant women.
The vaccine should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.
\*\*Breast-feeding:\*\*
There is no clinical data on the use of HBVAXPRO in breast-feeding women.4.7 Effects on ability to drive and use machines
No studies on the effects on the ability to drive and use machines have been performed. However, HBVAXPRO is expected to have no or negligible influence on the ability to drive and use machines.4.8 Undesirable effects
\*\*\*a. Summary of the safety profile\*\*\*
The most common side effects seen are injection-site reactions: transient soreness, erythema, induration.
\*\*\*b. Tabulated summary of adverse reactions\*\*\*
The following undesirable effects have been reported following the widespread use of the vaccine.
As with other hepatitis B vaccines, in many instances, the causal relationship to the vaccine has not been established.
| | |
| --- | --- |
| \*\*Adverse reactions\*\* | \*\*Frequency\*\* |
| \*General disorders and administration site conditions\* | |
| Local reactions (injection site): Transient soreness, Erythema, Induration | Common (≥1/100 to, <1/10) |
| Fatigue, Fever, Malaise, Influenza-like symptoms | Very rare (<1/10,000) |
| \*Blood and the lymphatic system disorders\* | |
| Thrombocytopaenia, Lymphadenopathy | Very rare (<1/10,000) |
| \*Immune system disorders\* | |
| Serum sickness, Anaphylaxis, Polyarteritis nodosa | Very rare (<1/10,000) |
| \*Nervous system disorders\* | |
| Paresthesia, Paralysis (including Bell's palsy, facial paralysis), Peripheral neuropathies (polyradiculoneuritis, Guillain Barre Syndrome), Neuritis (including optical neuritis), Myelitis (including transverse Myelitis), Encephalitis, Demyelinating disease of the central nervous system, Exacerbation of multiple sclerosis, Multiple sclerosis, Seizure, Headache, Dizziness, Syncope | Very rare (<1/10,000) |
| \*Eye disorders\* | |
| Uveitis | Very rare (<1/10,000) |
| \*Vascular disorders\* | |
| Hypotension, Vasculitis | Very rare (<1/10,000) |
| \*Respiratory, thoracic and mediastinal disorders\* | |
| Bronchospasm-like symptoms | Very rare (<1/10,000) |
| \*Gastrointestinal disorders\* | |
| Vomiting, Nausea, Diarrhoea, Abdominal pain | Very rare (<1/10,000) |
| \*Skin and subcutaneous tissue disorders\* | |
| Rash, Alopecia, Pruritus, Urticaria, Erythema multiforme, Angioedema, Eczema | Very rare (<1/10,000) |
| \*Musculoskeletal, connective tissue and bone disorders\* | |
| Arthralgia, Arthritis, Myalgia, Pain in extremity | Very rare (<1/10,000) |
| \*Investigations\* | |
| Elevation of liver enzymes | Very rare (<1/10,000) |
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.4.9 Overdose
There have been reports of administration of higher than recommended doses of HBVAXPRO.
In general, the adverse event profile reported with overdose was comparable to that observed with the recommended dose of HBVAXPRO.
- Instruction Pharmacology
- 5.1 Pharmacodynamic properties
Pharmacotherapeutic group: anti-infectious, ATC code: J07BC01
The vaccine induces specific humoral antibodies against hepatitis B virus surface antigen (anti-HBsAg). Development of an antibody titre against hepatitis B virus surface antigen (anti-HBsAg) equal to or greater than 10 IU/l measured 1 to 2 months after the last injection correlates with protection to hepatitis B virus infection.
In clinical trials, 96 % of 1,497 healthy infants, children, adolescents and adults given a 3 dose course of a previous formulation of Merck's recombinant hepatitis B vaccine developed a protective level of antibodies against hepatitis B virus surface antigen (≥ 10 IU/l).
Although the duration of the protective effect of a previous formulation of Merck's recombinant hepatitis B vaccine in healthy vaccinees is unknown, follow-up over 5-9 years of approximately 3,000 high-risk subjects given a similar plasma-derived vaccine has revealed no cases of clinically apparent hepatitis B infection.
In addition, persistence of vaccine-induced immunologic memory for hepatitis B virus surface antigen (HBsAg) has been demonstrated through an anamnestic antibody response to a booster dose of a previous formulation of Merck's recombinant hepatitis B vaccine in healthy adults.
In accordance with standard medical practice for hepatitis B vaccine administration, regular antibody testing should be done in haemodialysis patients. A booster dose should be given when antibody levels decline below 10 IU/l. In subjects in whom insufficient antibody titres are achieved after boosting, the use of alternative hepatitis B vaccines should be considered.
\*Reduced risk of Hepatocellular Carcinoma\*
Hepatocellular carcinoma is a serious complication of hepatitis B virus infection. Studies have demonstrated the link between chronic hepatitis B infection and hepatocellular carcinoma and 80 % of hepatocellular carcinomas are caused by hepatitis B virus infection. Hepatitis B vaccine has been recognised as the first anti-cancer vaccine because it can prevent primary liver cancer.5.2 Pharmacokinetic properties
Not applicable.5.3 Preclinical safety data
Animal reproduction studies have not been conducted.
- Instruction Pharmaceutical Particulars
- 6.1 List of excipients
Sodium chloride
Borax
Water for injections.6.2 Incompatibilities
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.6.3 Shelf life
3 years.6.4 Special precautions for storage
Store in a refrigerator (2 °C – 8 °C).
Do not freeze. Store in the original package in order to protect from light.
HBVAXPRO should be administered as soon as possible after being removed from refrigeration. HBVAXPRO can be administered provided total (cumulative multiple excursion) time out of refrigeration (at temperatures between 8°C and 25°C) does not exceed 72 hours. Cumulative multiple excursions between 0°C and 2°C are also permitted as long as the total time between 0°C and 2°C does not exceed 72 hours. These are not, however, recommendations for storage.6.5 Nature and contents of container
1 mL of suspension in vial (glass) with stopper (gray butyl rubber) and aluminum seals with plastic flip caps. Pack size of 1.6.6 Special precautions for disposal and other handling
The vaccine should be inspected visually in order to detect any appearance of precipitate or discolouring of the content prior to administration. If these conditions exist, the product should not be administered.
Before use, the vial should be well shaken.
Once the vial has been penetrated, the withdrawn vaccine should be used promptly, and the vial must be discarded.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
- Instruction Content
- ## Composition
One dose (1 mL) contains:
Hepatitis B virus surface antigen, recombinant (HBsAg) \\* 40 micrograms
Adsorbed on amorphous aluminium hydroxyphosphate sulfate (0.50 milligram Al+)
\\* produced in \*Saccharomyces cerevisiae\* (strain 2150-2-3) yeast by recombinant DNA technology.
This vaccine may contain traces of formaldehyde and potassium thiocyanate which are used during the manufacturing process. See sections 4.3, 4.4 and 4.8.
Excipient(s) with known effect:
Sodium less than 1mmol (23 mg) per dose.
For the full list of excipients, see section 6.1.
## Pharmaceutical Form
Suspension for injection
Slightly opaque white suspension.
## Clinical Particulars
4.1 Therapeutic indications
HBVAXPRO is indicated for the active immunisation against hepatitis B virus infection caused by all known subtypes in predialysis and dialysis adult patients.
It can be expected that hepatitis D will also be prevented by immunisation with HBVAXPRO as hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection.4.2 Posology and method of administration
\*\*Posology\*\*
Predialysis and dialysis adult patients: 1 dose (1 mL) at each injection.
\*\*\*Primary vaccination\*\*:\*
A course of vaccination should include three injections:
Schedule 0, 1, 6 months: two injections with an interval of one month; a third injection 6 months after the first administration.
\*\*\*Booster:\*\*\*
A booster dose must be considered in these vaccinees if the antibody level against hepatitis B virus surface antigen (anti-HBsAg) after primary series is less than 10 IU/l.
In accordance with standard medical practice for hepatitis B vaccine administration, regular antibody testing should be done in haemodialysis patients. A booster dose should be given when antibody levels decline below 10 IU/l.
\*\*Special dosage recommendations for known or presumed exposure to hepatitis B virus (e.g. needlestick with contaminated needle):\*\*
- Hepatitis B immunoglobulin should be given as soon as possible after exposure (within 24 hours).
- The first dose of the vaccine should be given within 7 days of exposure and can be administered simultaneously with hepatitis B immunoglobulin but at a separate injection site.
- Serologic testing is also recommended, with the administration of subsequent doses of vaccine, if necessary, (i.e. according to the serologic status of the patient) for short and long term protection.
- In the case of unvaccinated or incompletely vaccinated individuals, additional doses should be given as in the recommended immunisation schedule.
\*\*Method of administration\*\*
This vaccine should be administered intramuscularly.
The deltoid muscle is the preferred site for injection in adults.
Do not inject intravascularly.
Exceptionally, the vaccine may be administered subcutaneously in patients with thrombocytopaenia or bleeding disorders.
Precautions to be taken before handling or administering the product: see section 6.6.4.3 Contraindications
- History of hypersensitivity to the active substance, or to any of the excipients, or trace residuals (e.g. formaldehyde and potassium thiocyanate), see sections 6.1 and 6.2.
- Vaccination should be postponed in individuals with a severe febrile illness or acute infection.4.4 Special warnings and precautions for use
\*\*Traceability\*\*
In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.
As with all injectable vaccines, appropriate medical treatment should always be readily available in case of rare anaphylactic reactions following the administration of the vaccine (see section 4.8).
This vaccine may contain traces of formaldehyde and potassium thiocyanate which are used during the manufacturing process. Therefore, hypersensitivity reactions may occur (see sections 2 and 4.8).
Use caution when vaccinating latex-sensitive individuals since the vial stopper contains dry natural latex rubber that may cause allergic reactions.
A number of factors have been observed to reduce the immune response to hepatitis B vaccines. These factors include older age, male gender, obesity, smoking, route of administration and some chronic underlying diseases. Consideration should be given to serological testing of those subjects who may be at risk of not achieving seroprotection following a complete course of HBVAXPRO. Additional doses may need to be considered for persons who do not respond or have a sub-optimal response to a course of vaccinations.
Because of the long incubation period of hepatitis B, it is possible for unrecognised hepatitis B infection to be present at the time of vaccination. The vaccine may not prevent hepatitis B infection in such cases.
The vaccine will not prevent infection caused by other agents such as hepatitis A, hepatitis C and hepatitis E and other pathogens known to infect the liver.
Caution should be exercised when prescribing to pregnant or breast-feeding women (see section 4.6).
Excipient(s) with known effect:
This medicinal product contains less than 1mmol sodium (23 mg) per dose, and is considered to be essentially sodium free.4.5 Interaction with other medicinal products and other forms of interaction
This vaccine can be administered:
- with hepatitis B immunoglobulin, at a separate injection site.
- to complete a primary immunisation course or as a booster dose in subjects who have previously received another hepatitis B vaccine.
- concomitantly with other vaccines, using separate sites and syringes.4.6 Fertility, pregnancy and lactation
\*\*Fertility:\*\*
HBVAXPRO has not been evaluated in fertility studies.
\*\*Pregnancy:\*\*
There is no clinical data on the use of HBVAXPRO in pregnant women.
The vaccine should be used during pregnancy only if the potential benefit justifies the potential risk to the foetus.
\*\*Breast-feeding:\*\*
There is no clinical data on the use of HBVAXPRO in breast-feeding women.4.7 Effects on ability to drive and use machines
No studies on the effects on the ability to drive and use machines have been performed. However, HBVAXPRO is expected to have no or negligible influence on the ability to drive and use machines.4.8 Undesirable effects
\*\*\*a. Summary of the safety profile\*\*\*
The most common side effects seen are injection-site reactions: transient soreness, erythema, induration.
\*\*\*b. Tabulated summary of adverse reactions\*\*\*
The following undesirable effects have been reported following the widespread use of the vaccine.
As with other hepatitis B vaccines, in many instances, the causal relationship to the vaccine has not been established.
| | |
| --- | --- |
| \*\*Adverse reactions\*\* | \*\*Frequency\*\* |
| \*General disorders and administration site conditions\* | |
| Local reactions (injection site): Transient soreness, Erythema, Induration | Common (≥1/100 to, <1/10) |
| Fatigue, Fever, Malaise, Influenza-like symptoms | Very rare (<1/10,000) |
| \*Blood and the lymphatic system disorders\* | |
| Thrombocytopaenia, Lymphadenopathy | Very rare (<1/10,000) |
| \*Immune system disorders\* | |
| Serum sickness, Anaphylaxis, Polyarteritis nodosa | Very rare (<1/10,000) |
| \*Nervous system disorders\* | |
| Paresthesia, Paralysis (including Bell's palsy, facial paralysis), Peripheral neuropathies (polyradiculoneuritis, Guillain Barre Syndrome), Neuritis (including optical neuritis), Myelitis (including transverse Myelitis), Encephalitis, Demyelinating disease of the central nervous system, Exacerbation of multiple sclerosis, Multiple sclerosis, Seizure, Headache, Dizziness, Syncope | Very rare (<1/10,000) |
| \*Eye disorders\* | |
| Uveitis | Very rare (<1/10,000) |
| \*Vascular disorders\* | |
| Hypotension, Vasculitis | Very rare (<1/10,000) |
| \*Respiratory, thoracic and mediastinal disorders\* | |
| Bronchospasm-like symptoms | Very rare (<1/10,000) |
| \*Gastrointestinal disorders\* | |
| Vomiting, Nausea, Diarrhoea, Abdominal pain | Very rare (<1/10,000) |
| \*Skin and subcutaneous tissue disorders\* | |
| Rash, Alopecia, Pruritus, Urticaria, Erythema multiforme, Angioedema, Eczema | Very rare (<1/10,000) |
| \*Musculoskeletal, connective tissue and bone disorders\* | |
| Arthralgia, Arthritis, Myalgia, Pain in extremity | Very rare (<1/10,000) |
| \*Investigations\* | |
| Elevation of liver enzymes | Very rare (<1/10,000) |
Reporting of suspected adverse reactions
Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA Yellow Card in the Google Play or Apple App Store.4.9 Overdose
There have been reports of administration of higher than recommended doses of HBVAXPRO.
In general, the adverse event profile reported with overdose was comparable to that observed with the recommended dose of HBVAXPRO.
## Pharmacological Properties
5.1 Pharmacodynamic properties
Pharmacotherapeutic group: anti-infectious, ATC code: J07BC01
The vaccine induces specific humoral antibodies against hepatitis B virus surface antigen (anti-HBsAg). Development of an antibody titre against hepatitis B virus surface antigen (anti-HBsAg) equal to or greater than 10 IU/l measured 1 to 2 months after the last injection correlates with protection to hepatitis B virus infection.
In clinical trials, 96 % of 1,497 healthy infants, children, adolescents and adults given a 3 dose course of a previous formulation of Merck's recombinant hepatitis B vaccine developed a protective level of antibodies against hepatitis B virus surface antigen (≥ 10 IU/l).
Although the duration of the protective effect of a previous formulation of Merck's recombinant hepatitis B vaccine in healthy vaccinees is unknown, follow-up over 5-9 years of approximately 3,000 high-risk subjects given a similar plasma-derived vaccine has revealed no cases of clinically apparent hepatitis B infection.
In addition, persistence of vaccine-induced immunologic memory for hepatitis B virus surface antigen (HBsAg) has been demonstrated through an anamnestic antibody response to a booster dose of a previous formulation of Merck's recombinant hepatitis B vaccine in healthy adults.
In accordance with standard medical practice for hepatitis B vaccine administration, regular antibody testing should be done in haemodialysis patients. A booster dose should be given when antibody levels decline below 10 IU/l. In subjects in whom insufficient antibody titres are achieved after boosting, the use of alternative hepatitis B vaccines should be considered.
\*Reduced risk of Hepatocellular Carcinoma\*
Hepatocellular carcinoma is a serious complication of hepatitis B virus infection. Studies have demonstrated the link between chronic hepatitis B infection and hepatocellular carcinoma and 80 % of hepatocellular carcinomas are caused by hepatitis B virus infection. Hepatitis B vaccine has been recognised as the first anti-cancer vaccine because it can prevent primary liver cancer.5.2 Pharmacokinetic properties
Not applicable.5.3 Preclinical safety data
Animal reproduction studies have not been conducted.
## Pharmaceutical Particulars
6.1 List of excipients
Sodium chloride
Borax
Water for injections.6.2 Incompatibilities
In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products.6.3 Shelf life
3 years.6.4 Special precautions for storage
Store in a refrigerator (2 °C – 8 °C).
Do not freeze. Store in the original package in order to protect from light.
HBVAXPRO should be administered as soon as possible after being removed from refrigeration. HBVAXPRO can be administered provided total (cumulative multiple excursion) time out of refrigeration (at temperatures between 8°C and 25°C) does not exceed 72 hours. Cumulative multiple excursions between 0°C and 2°C are also permitted as long as the total time between 0°C and 2°C does not exceed 72 hours. These are not, however, recommendations for storage.6.5 Nature and contents of container
1 mL of suspension in vial (glass) with stopper (gray butyl rubber) and aluminum seals with plastic flip caps. Pack size of 1.6.6 Special precautions for disposal and other handling
The vaccine should be inspected visually in order to detect any appearance of precipitate or discolouring of the content prior to administration. If these conditions exist, the product should not be administered.
Before use, the vial should be well shaken.
Once the vial has been penetrated, the withdrawn vaccine should be used promptly, and the vial must be discarded.
Any unused medicinal product or waste material should be disposed of in accordance with local requirements.
- Company Detail Path
- /organization/merck-sharp-and-dohme-uk-limited
